IMNM PE Ratio & Valuation,Is IMNM Overvalued

IMNM Relative Valuation

IMNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMNM is overvalued; if below, it's undervalued.

Historical Valuation

Immunome Inc (IMNM) is now in the Fair zone, suggesting that its current forward PS ratio of 743.95 is considered Fairly compared with the five-year average of -5.52. The fair price of Immunome Inc (IMNM) is between 4.77 to 31.69 according to relative valuation methord.

Relative Value

Fair Zone

4.77-31.69

Current Price：24.63

Fair

-7.91

-6.59

EV/EBITDA

Immunome Inc. (IMNM) has a current EV/EBITDA of -6.59. The 5-year average EV/EBITDA is -0.93. The thresholds are as follows: Strongly Undervalued below -4.34, Undervalued between -4.34 and -2.64, Fairly Valued between 0.77 and -2.64, Overvalued between 0.77 and 2.48, and Strongly Overvalued above 2.48. The current Forward EV/EBITDA of -6.59 falls within the Strongly Undervalued range.

-6.24

EV/EBIT

Immunome Inc. (IMNM) has a current EV/EBIT of -6.24. The 5-year average EV/EBIT is -3.46. The thresholds are as follows: Strongly Undervalued below -10.17, Undervalued between -10.17 and -6.82, Fairly Valued between -0.11 and -6.82, Overvalued between -0.11 and 3.24, and Strongly Overvalued above 3.24. The current Forward EV/EBIT of -6.24 falls within the Historic Trend Line -Fairly Valued range.

743.95

Immunome Inc. (IMNM) has a current PS of 743.95. The 5-year average PS is 141.31. The thresholds are as follows: Strongly Undervalued below -472.12, Undervalued between -472.12 and -165.41, Fairly Valued between 448.03 and -165.41, Overvalued between 448.03 and 754.74, and Strongly Overvalued above 754.74. The current Forward PS of 743.95 falls within the Overvalued range.

-8.12

P/OCF

Immunome Inc. (IMNM) has a current P/OCF of -8.12. The 5-year average P/OCF is -3.88. The thresholds are as follows: Strongly Undervalued below -10.73, Undervalued between -10.73 and -7.30, Fairly Valued between -0.45 and -7.30, Overvalued between -0.45 and 2.97, and Strongly Overvalued above 2.97. The current Forward P/OCF of -8.12 falls within the Undervalued range.

-8.12

P/FCF

Immunome Inc. (IMNM) has a current P/FCF of -8.12. The 5-year average P/FCF is -3.70. The thresholds are as follows: Strongly Undervalued below -12.04, Undervalued between -12.04 and -7.87, Fairly Valued between 0.48 and -7.87, Overvalued between 0.48 and 4.65, and Strongly Overvalued above 4.65. The current Forward P/FCF of -8.12 falls within the Undervalued range.

Immunome Inc (IMNM) has a current Price-to-Book (P/B) ratio of 6.80. Compared to its 3-year average P/B ratio of 5.50 , the current P/B ratio is approximately 23.58% higher. Relative to its 5-year average P/B ratio of 4.62, the current P/B ratio is about 47.23% higher. Immunome Inc (IMNM) has a Forward Free Cash Flow (FCF) yield of approximately -10.69%. Compared to its 3-year average FCF yield of -13.98%, the current FCF yield is approximately -23.53% lower. Relative to its 5-year average FCF yield of -18.29% , the current FCF yield is about -41.57% lower.

6.80

P/B

Median3y

5.50

Median5y

4.62

-10.69

FCF Yield

Median3y

-13.98

Median5y

-18.29

Competitors Valuation Multiple

The average P/S ratio for IMNM's competitors is 509.06, providing a benchmark for relative valuation. Immunome Inc Corp (IMNM) exhibits a P/S ratio of 743.95, which is 46.14% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of IMNM increased by 84.27% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.70 to -6.96.

The secondary factor is the Margin Expansion, contributed 26.84%to the performance.

Overall, the performance of IMNM in the past 1 year is driven by P/E Change. Which is more unsustainable.

-100.00%

2.91M → 0.00

Revenue Growth

26.84%

-1.62K → -2.05K

Margin Expansion

157.43%

-2.70 → -6.96

P/E Change

84.27%

10.62 → 19.57

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Immunome Inc (IMNM) currently overvalued or undervalued?

What is Immunome Inc (IMNM) fair value?

IMNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Immunome Inc (IMNM) is between 4.77 to 31.69 according to relative valuation methord.

How does IMNM's valuation metrics compare to the industry average?

What is the current P/B ratio for Immunome Inc (IMNM) as of Dec 15 2025?

As of Dec 15 2025, Immunome Inc (IMNM) has a P/B ratio of 6.80. This indicates that the market values IMNM at 6.80 times its book value.

What is the current FCF Yield for Immunome Inc (IMNM) as of Dec 15 2025?

As of Dec 15 2025, Immunome Inc (IMNM) has a FCF Yield of -10.69%. This means that for every dollar of Immunome Inc’s market capitalization, the company generates -10.69 cents in free cash flow.

What is the current Forward P/E ratio for Immunome Inc (IMNM) as of Dec 15 2025?

As of Dec 15 2025, Immunome Inc (IMNM) has a Forward P/E ratio of -7.91. This means the market is willing to pay $-7.91 for every dollar of Immunome Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Immunome Inc (IMNM) as of Dec 15 2025?

As of Dec 15 2025, Immunome Inc (IMNM) has a Forward P/S ratio of 743.95. This means the market is valuing IMNM at $743.95 for every dollar of expected revenue over the next 12 months.

IMNM Valuation